Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Humanin and Vilon — mechanism, dosing, side effects, legal status, and pricing.
Humanin is a mitochondrial-derived peptide encoded within the 16S ribosomal RNA gene. It was discovered through its ability to protect neurons from Alzheimer's disease-related toxicity and is studied for neuroprotection, metabolic regulation, and anti-aging applications.
Vilon is a synthetic dipeptide (Lys-Glu / KE) from the Khavinson bioregulator series, originally derived from thymus extracts and studied in Russian preclinical models as an immunomodulator and geroprotector. Not FDA-approved; all published evidence originates from a single research group.
Humanin
Vilon
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Humanin
Vilon
COA corpus from Disclosed Labs — independently tested batches only.
Humanin
3
COAs
99.5%
Avg purity
2
Labs
Vilon
11
COAs
99.7%
Avg purity
6
Labs
Hashimoto et al. (2001) discovered humanin through functional screening for neuroprotective factors against amyloid-beta toxicity. Yen et al. characterized the S14G-Humanin analog (HNG) as 1000x more potent. Muzumdar et al. demonstrated that humanin improves insulin sensitivity and reduces visceral fat in animal models. Circulating humanin levels decline with age and correlate inversely with Alzheimer's biomarkers. Cohen et al. showed humanin's role in the GH/IGF-1 axis through IGFBP-3 interaction. No human clinical trials have been conducted — all dosing is extrapolated from preclinical data.
Key references
Evidence is limited to Khavinson-group preclinical work. Khavinson & Anisimov (Dokl Biol Sci, 2000; PMID 10944717) reported that Vilon (L-Lys-L-Glu) inhibited spontaneous tumor growth and extended lifespan in CBA mice. A small Russian report on Vilon as an adjuvant in elderly colorectal-cancer patients (Kuznik et al., 2005; PMID 16075684) is non-randomized and unreplicated. No Western-framework clinical trials, pharmacokinetic, or dose-response studies have been published.
Humanin (Cognitive) and Vilon (Immune) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Half-life
Side Effects
Contraindications
Lab Testing
Disclosed Labs